New Hope Network is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Bioiberica to showcase Hyal-Joint at Supplyside West, Las Vegas, NV, USA

Since Bioiberica launched Hyal-Joint™ brand of hyaluronic acid (HA), the category has experienced a number of new events and studies.

At the next Supplyside exhibition, Dr Theodosakis will be in the Biobérica booth to explain why he recommends Hyal-Joint as the best oral hyaluronic acid. Dr Theodosakis has recently joined Bioiberica as a medical advisory member. He will assist in clinical studies design and development and, as a scientific expert, he will respond to questions and concerns of customers.

Dr. Theo is considered one of the world's foremost authorities on osteoarthritis treatments, including the use of glucosamine/chondroitin, HA (Hyal-joint™) and other supplements.

Why does he support Hyal-Joint™?

Differences between Hyaluronic acid include both chemical/composition differences and efficacy differences. Hyal-joint is the richest product in Hyaluronic acid among natural materials and is more efficacious than the synthetic form.

When comparing with hyaluronic acid from fermentation, efficacy differences have been proved: Hyal-Joint™ is more capable to stimulate endogenous synthesis of HA. This is key since the efficacy of HA in joint health is related to synovial fluid health.

Synovial fluid is the lubricant for the joint, and its properties are mainly due to HA content. In joint problems like osteoarthritis, there is a decrease of HA in the synovial fluid and the function of the joint is affected. That’s why the effect of Hyal-Joint is so important and beneficial.

Other differences include the level of science that supports each product: Hyal-Joint™ has already proven efficacy in many in vitro studies (anti-inflammatory effect, stimulation of natural HA synthesis, absorption…), in vivo data in humans and in horses. The first clinical pilot trial is complete and a second clinical trial with Hyal-Joint™ will be completed in early 2008.

Bioiberica will continue to research Hyal-Joint™ to position it at the top of the HA category.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.